Effects of centrally administered anxiolytic compounds in animal models of anxiety

Neuroscience and Biobehavioral Reviews

Volumn 23, Issue 4, 1999, Pages 591-613

  Menard, Janet ^a   Treit, Dallas ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Animal models of anxiety; Anxiolytics; Benzodiazapines; Intra cerebral drug infusion; Neuropeptides; Serotonergics

Indexed keywords

1 (1 METHYL 5 INDOLYL) 3 (3 PYRIDYL)UREA; 1 [5 (2 THIENYLMETHOXY) 3 INDOLYL] 2 PROPANAMINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 5 ISOPROPOXY 4 METHYL BETA CARBOLINE 3 CARBOXYLIC ACID ETHYL ESTER; ALPHA METHYLSEROTONIN; ANXIOLYTIC AGENT; BEMESETRON; BENZODIAZEPINE DERIVATIVE; BETA CARBOLINE DERIVATIVE; BUSPIRONE; CHLORDIAZEPOXIDE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR[9-41]; DIAZEPAM; FLUMAZENIL; GEPIRONE; IPSAPIRONE; KETANSERIN; METHYSERGIDE; MIDAZOLAM; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N METHYL BETA CARBOLINE 3 CARBOXAMIDE; NEUROPEPTIDE Y; ONDANSETRON; SEROTONIN 1A AGONIST; SEROTONIN 2 AGONIST; SEROTONIN 3 AGONIST; SEROTONIN AGONIST; TERTATOLOL; TROPISETRON; UNCLASSIFIED DRUG; WAY 100365;

AMYGDALOID NUCLEUS; ANIMAL MODEL; ANXIETY; DORSAL RAPHE NUCLEUS; DRUG EFFECT; EXPERIMENTAL TEST; HIPPOCAMPUS; HYPOTHALAMUS; INTRACEREBRAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; REVIEW; SEPTUM PELLUCIDUM; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BRAIN; HUMANS; INJECTIONS; MODELS, PSYCHOLOGICAL;

EID: 0033018708     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7634(98)00056-6     Document Type: Review

References (156)

1. 1A receptors in the median raphe nucleus and dorsal hippocampus may mediate anxiolytic and anxiogenic behaviours respectively. Eur J Pharmacol. 264:1994;259-264.
2. Barnett SA. The rat: a study in behaviour. London: Metheun, 1963.
3. Belcheva I., Belcheva S., Petkov V.V., Petkov V.D. Hippocampal asymmetry in the behavioural responses to the 5-HT1A receptor agonist 8-OH-DPAT. Brain Res. 640:1994;223-228.
4. Blier P., Serrano A., Scatton B. Differential responsiveness of the rat dorsal and median raphe 5-HT system to 5-HT1 receptor agonists and p-chloroamphetamine. Synapse. 5:1990;120-133.
5. Blier P., Steinberg S., Chaput Y., de Montigny C. Electrophysiological assessment of putative antagonists of 5-hydroxytryptamine receptors: a single cell study in the rat dorsal raphe nucleus. Can J Physiol Pharmacol. 67:1989;98-105.
6. Blumberg M.S., Alberts J.R. On the significance of similarities between ultrasonic vocalizations of infant and adult rats. Neurosci Biobehav Rev. 15:1991;383-390.
7. Butler P.D., Weiss J.M., Stout J.C., Nemeroff C.B. Corticotrophin-releasing factor produces fear-enhancing and behavioural activating effects following infusion into the locus coeruleus. J Neurosci. 10:1990;176-183.
8. Carli M., Prontera C., Samanin R. Evidence that central 5-hydroxytryptaminergic neurones are involved in the anxiolytic activity of buspirone. Br J Pharmacol. 96:1989;829-836.
9. Carli M., Samanin R. Potential anxiolytic properties of 8-hydroxy-2-(Di-N-propylamino)tetralin, a selective serotonin 1A receptor agonist. Psychopharmacology. 94:1988;84-91.
10. Cervo L., Grignaschi G., Samanin R. 8-Hydroxy-2-(di-n-propylamino)tetralin, a selective serotonin 1A receptor agonist, reduces the immobility of rats in the forced swimming test by acting on the nucleus rahe dorsalis. Eur J Pharmacol. 158:1988;53-59.
11. Charney D.S., Woods S.W., Goodman W.K., Heninger G.R. Serotonin function in anxiety. II. Effects of the serotonin agonist mCPP on panic disorder patients and healthy subjects. Psychopharmacology. 92:1987;14-21.
12. Connor H., Higgins G.A. Cardiovascular effects of 5-HT 1A receptor agonists injected into the dorsal raphe nucleus of concious rats. Eur J Pharmacol. 182:1990;63-72.
13. A receptors and anxiety: from neurobiology to treatment. New York: Raven Press, 1995:75-92.
14. Costall B., Kelly M.E., Naylor R.J., Onaivi E.S. Actions of buspirone in a putative model of anxiety in the mouse. J Pharm Pharmacol. 40:1988;494-500.
15. Costall B., Kelly M.E., Naylor R.J., Onaivi E.S., Tyers M.B. Neuroanatomical sites of action of 5-HT3 receptor agonists and antagonists for alteration of aversive behaviour in the mouse. Br J Pharmacol. 96:1989;325-332.
16. Crawley J.N. Exploratory behaviour models of anxiety in mice. Neurosci Biobehav Rev. 9:1985;37-44.
17. Crawley J.N., Goodwin F.K. Preliminary report of a simple animal behaviour model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav. 13:1980;167-170.
18. Davis M. The role of the amygdala in fear and anxiety. Ann Rev Neurosci. 15:1992;33-375.
19. Davis M. Pharmacological and anatomical analysis of fear conditioning using the fear-potentiated startle paradigm. Behav Neurosci. 100:1986;814-824.
20. 1A receptors in depression and anxiety. New York, Raven Press: 1992, 83-98.
21. 1A receptor agonists: recent developments and controversial issues. Psychopharmacology. 121:1995;1-26.
22. 1A receptors in depression and anxiety. New York: Raven Press, 1992:55-81.
23. De Vry J.M., Ulrich B., Schrieber R., Traber J. Shock-induced ultrasonic vocalization in young adult rats: a model for testing putative anti-anxiety drugs. Eur J Pharmacol. 249:1993;331-339.
24. Drugan R.C., Skolnick P., Paul S.M., Crawley J. Low doses of muscimol produce anticonflict actions in the lateral septum of the rat. Neuropsychopharmacology. 25:1986;203-205.
25. Dunn A.J., Berridge C.W. Physiological and behavioural responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res Rev. 15:1990;71-100.
26. Duxon M.S., Beckett S.R., Baxter G.S., Blackburn T.P., Fone K.C. Intra-amygdala injection of the 5-HT2B receptor agonist BW 723C86 produces anxiolysis on the elevated plus-maze in the rate. Br J Pharmacol. 116:1995;331P.
27. Duxon M.S., Flanigan T.P., Reavley A.C., Baxter G.S., Blackburn T.P., Fone K.C. Evidence for expression of the 5-hydroxytryptamine 2B receptor protein in the rat central nervous system. Neuroscience. 76:1997;323-329.
28. Duxon M.S., Kennett G.A., Lightowler S., Blackburn T.P., Fone K.C. Activation of 5-HT2B receptors in the medial amygdala causes anxiolysis in the social interaction test in the rat. Neuropharmacology. 36:1997;601-608.
29. Duxon M.S., Reavley A.C., Flanigan T.P., Baxter G., Blackburn T.P., Fone K.C. Expression of the 5-HT2B receptor protein in the rat brain. Br J Pharmacol. 115:1995;105P.
30. Fanselow M.S., Helmstetter F.J. Conditional analgesia, defensive freezing, and benzodiazepines. Behav Neurosci. 102:1988;233-243.
31. File S.E. Animal models for predicting clinical efficacy of anxiolytic drugs: social behaviour. Neuropsychobiology. 13:1985;55-62.
32. File S. E. The contribution of behavioural studies to the neuropharmacology of anxiety. Neuropharmacology. 26:1987;877-886.
33. File S. E., Gonzalez L. E. Anxiolytic effects in the plus-maze of 5-HT1A-receptor ligands in dorsal raphe and ventral hippocampus. Pharmacol. Biochem. Behav. 54:1996;123-128.
34. File S. E., Gonzalez L. E., Andrews N. Comparative study of pre- and postsynaptic 5-HT1A receptor modulation of anxiety in two ethological animal tests. J Neurosci. 16:1996;4810-4815.
35. File S. E., Hyde J. R. G. A test of anxiety that distinguishes between the actions of benzodiazepines and those of other minor tranquilisers and stimulants. Pharmacol Biochem Behav. 11:1979;65-69.
36. File S. E., Hyde J. R. G. Can social interaction be used to measure anxiety? Br J Pharmacol. 62:1978;19-24.
37. Fletcher A., Cliffe I. A., Dourish C. T. Silent 5-HT1A receptor antagonists: utility as research tools and therapeutic agents. Tips. 14:1993;441-448.
38. Gardner C. R. Functional in vivo correlates of the benzodiazepine agonist-inverse agonist continuum. Prog Neurobiol. 31:1988;425-476.
39. Geller I., Seifter J. The effects of meprobamate, barbiturates, D-amphetamine and promazine on experimentally induced conflict in the rat. Psychopharmacology. 1:1960;482-492.
40. 1A receptors in depression and anxiety, Stahl SM, Gastpar M, Keppel JM, Hesselink D, Traber J, editors. New York: Raven Press, 1992:35-53.
41. Gonzalez L. E., Andrews N., File S. E. 5-HT1A and benzodiazepine receptors in the basolateral amygdala modulate anxiety in the social interaction test, but not in the elevated plus-maze test. Brain Res. 732:1996;145-153.
42. Gonzalez L. E., File S. E. A five minute experience in the elevated plus-maze alters the state of the benzodiazepine receptor in the dorsal raphe nucleus. J Neurosci. 17:1997;1505-1511.
43. Gray T. S., Bingaman E. W. The amygdala: corticotropin-releasing factor, steroids, and stress. Crit Rev Neurobiol. 10:1996;155-168.
44. Green S., Hodges H. Differential effects of dorsal raphe lesions and intraraphe GABA and benzodiazepines on conflict behaviour in rats. Behav Neural Biol. 46:1986;13-29.
45. Green S., Vale A. L. Role of amygdaloid nuclei in the anxiolytic effects of benzodiazepines in rats. Behav Pharmacol. 3:1992;261-264.
46. Greenshaw AJ. Electrical and chemical stimulation of brain tissue in vivo. In: Neuromethods, Vol. 32: In Vivo Neuromethods, Boulton A, Baker GB, Bateson AN, editors. New Jersey: Humana Press, 1998:359-381.
47. Griebel G. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years research. Pharmacol Ther. 65:1995;319-395.
48. Haefely W, Bonettii EP, Bukard R, Cumin J, Laurent JP, Mohler H, Pieri L, Polc P, Richards JG, Schaffner R, Scherschlict R. Benzodiazepine antagonists. In: Costa E., editor. The benzodiazepines: from molecular biology to clinical practice. New York: Raven Press, 1983:137-146.
49. Handley S. Future prospects for the pharmacological treatment of anxiety. CNS Drugs. 2:1994;397-414.
50. Heilig M. Antisense inhibition of neuropeptide Y (NPY)-Y1 receptor expression blocks the anxiolytic-like action of NPY in amygdala and paradoxically increases feeding. Regulatory Peptides. 59:1995;201-205.
51. Heilig M., Koob G. F., Ekman R., Britton K. T. Corticotropin-releasing factor and neuropeptide Y: role in emotional integration. Tins. 17:1994;80-85.
52. Heilig M., McLeod S., Brot M., Heirichs S. C., Menzaghi F., Koob G. F., Britton K. T. Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from food intake effects. Neuropsychopharmacology. 8:1993;357-363.
53. Heilig M., Soderpalm B., Engel J. A., Widerlov E. Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology. 98:1989;524-529.
54. Heinrichs S. C., Pich E. M., Miczek K. A., Britton K. T., Koob G. F. Corticotropin-releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotropic action. Brain Res. 581:1992;190-197.
55. Higgins G. A., Bradbury A. J., Jones B. J., Oakley N. R. Behavioural and biochemical consequences following activation of the 5-HT 1-like and GABA receptors in the dorsal raphe nucleus of the rat. Neuropharmacology. 27:1988;993-1001.
56. Higgins G. A., Elliott P. J. Differential behavioural activation following intra-raphe infusion of 5-HT 1A receptor agonists. Eur J Pharmacol. 193:1991;351-356.
57. Higgins G. A., Jones B. J., Oakley N. R. Effect of 5-HT 1A receptor agonists in two models of anxiety after dorsal raphe injection. Psychopharmacology. 106:1992;261-267.
58. Higgins G. A., Jones B. J., Oakley N. R., Tryers M. B. Evidence that the amygdala is involved in the disinhibitory effects of 5-HT3 receptor antagonists. Psychopharmacology. 104:1991;545-551.
59. Hillegaart V. Effects of local application of 5-HT and 8-OH-DPAT into the dorsal and median raphe nuclei on core temperature in the rat. Psychopharmacology. 103:1991;291-296.
60. Hillegaart V. Effects of local application of 5-HT and 8-OH-DPAT into the dorstal and median raphe nuclei on motor activity in the rat. Physiol Behav. 48:1990;143-148.
61. Hillegaart V., Hjorth S. Median raphe, but not dorsal raphe, application of the 5-HT1A agonist 8-OH-DPAT stimulates rat motor activity. Eur J Pharmacol. 160:1989;303-307.
62. Hindley S. W., Hobbs A., Paterson I. A., Roberts M. H. The effects of methyl β-carboline-3-carboxylate on social interaction and locomotor activity when microinjected into the nucleus raphe dorsalis of the rat. Br J Pharmacol. 86:1985;753-761.
63. 1A receptors in depression and anxiety, Stahl SM, Gastpar M, Keppel Hesselink JM, Traber J, editors. New York: Raven Press, 1992:109-117.
64. Hitchcock J., Davis M. Lesions of the amygdala, but not of the cerebellum or red nucleus, block conditioned fear as measured with the potentiated startle paradigm. Behav Neurosci. 100:1986;11-22.
65. Hjorth S., Sharp T. Effect of the 5-HT 1A receptor agonist 8-OH-DPAT on the release of 5-HT in dorsal and median raphe-innervated rat brain regions as measured by in vivo microdialysis. Life Sci. 48:1991;1779-1786.
66. Hodges H., Green S., Glenn B. Evidence that the amygdala is involved in benzodiazepine and serotonergic effects on punished responding but not on discrimination. Psychopharmacology. 92:1987;491-504.
67. Hogg S. A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol Biochem Behav. 4:1996;21-30.
68. Hogg S., Andrews N., File S. E. Contrasting behavioural effects of 8-OH-DPAT in the dorsal raphe nucleus and ventral hippocampus. Neuropharmacology. 33:1994;343-348.
69. Hoyer D., Clarke D. E., Fozard J. R., Hartig P. R., Martin G. R., Mylecharane E. J., Saxena P. R., Humphrey P. P. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev. 46:1994;157-203.
70. Hutson P. H., Sarna G. S., O'Connell M. T., Curzon G. Hippocampal 5-HT synthesis and release in vivo is decreased by infusion of 8-OH-DPAT into the nucleus raphe dorsalis. Neurosci Lett. 100:1989;276-280.
71. Invernizzi R., Carli M., Di Clemente A., Samanin R. Administration of 8-hydroxy-2-(di-n-propylamino)tetralin in raphe nuclei dorsalis and medianus reduces serotonin synthesis in the rat brain: differences in potency and regional sensitivity. J Neurochem. 56:1991;243-247.
72. Ireland S. J., Tyers M. B. Pharmacological characterization of 5-hydroxytryptamine-induced depolarization of the rat isolated vagus nerve. Br J Pharmacol. 90:1987;229-238.
73. Jolas T., Schreiber R., Laporte A. M., Chastanet M., De Vry J., Glaser T., Adrien J., Hamon M. Are post-synaptic 5-HT1A receptor agonists involved in the anxiolytic effects of 5-HT1A receptor agonists and in their inhibitory effects on the firing of serotonergic neurons in the rat. J Pharmacol Exp Ther. 272:1995;920-929.
74. Kalin N. H., Sherman J. E., Takahashi L. K. Antagonism of endogenous CRH systems attenuates stress-induced freezing behaviour in rats. Brain Res. 457:1988;130-135.
75. Kalin N. H., Takahashi L. K. Fear-motivated behaviour induced by prior shock experience is mediated by corticotropin-releasing hormone systems. Brain Res. 509:1990;80-84.
76. Kataoka Y., Shibata K., Gomita Y., Ueki S. The mammillary body is a potential site of antianxiety action of benzodiazepines. Brain Res. 241:1982;374-377.
77. Kataoka Y., Shibata K., Miyazaki A., Inoue Y., Tominaga K., Koizumi S., Ueki S., Niwa M. Involvement of the dorsal hippocampus in mediation of the antianxiety action of tandospirone, a 5-hydroxytryptamine 1A agonist anxiolytic. Neuropharmacology. 30:1991;475-480.
78. Kennett G. A., Curzon G. Evidence that mCPP may have behavioural effects mediated by 5-HT1C receptors. Br J Pharmacol. 94:1988;137-147.
79. Kennett G. A., Curzon G. Evidence that hypophagia induced by mCPP and TFMPP requires 5-HT1C and 5-HT1B receptors, hypophagia induced by RU 24969 only requires 5-HT1B receptors. Psychopharmacology. 96:1988;93-100.
80. Kilpatrick G. J., Jones B. J., Tyers M. B. Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature. 330:1987;745-748.
81. Kostowski W., Plaznik A., Stefanski R. Intra-hippocampal buspirone in animal models of anxiety. Eur J Pharmacol. 168:1989;393-396.
82. Kunovac J. L., Stahl S. M. Future directions in anxiolytic pharmacotherapy. Psychiatric Clinics of North America. 18:1995;895-909.
83. Lee Y., Davis M. Role of the septum in the excitatory effect of corticotropin-releasing hormone on the acoustic startle reflex. J Neurosci. 17:1997;6424-6433.
84. Lee Y., Davis M. Role of the hippocampus, the bed nucleus of the stria terminalis, and the amygdala in the excitatory effect of corticotropin-releasing hormone on the acoustic startle reflex. J Neurosci. 17:1997;6434-6446.
85. Leishman D. J., Boeijinga P. H., Galvan M. Differential effects of centrally-active antihypertensives on 5-HT1A receptors in rat dorso-lateral septum, rat hippocampus and guinea-pig hippocampus. Br J Pharmacol. 111:1994;318-324.
86. Liang K. C., Lee E. H. Intra-amygdala injections of corticotropin releasing factor facilitate inhibitory avoidance learning and reduce exploratory behaviour in rats. Psychopharmacology. 96:1988;232-236.
87. Liang K. C., Melia K. R., Miserendino M. J., Falls W. A., Campeau S., Davis M. Corticotropin-releasing factor: long-lasting facilitation of the acoustic startle reflex. J Neurosci. 12:1992;2303-2312.
88. Liang K. C., Melia K. R., Campeau S., Falls W. A., Miserendino M. J., Davis M. Lesions of the central nucleus of the amygdala, but not the paraventricular nucleus of the hypothalamus, block the excitatory effects of corticotropin-releasing factor on the acoustic startle reflex. J Neurosci. 12:1992;2313-2320.
89. Lister R. G. Ethologically based animal models of anxiety disorders. Pharmacol Ther. 46:1990;321-340.
90. McNamara R. K., Skelton R. W. Effects of intracranial infusions of chlordiazepoxide on spatial learning in the Morris water maze I. Neuroanatomical specificity. Behav Brain Res. 59:1993;175-191.
91. Melo L. L., Brandao M. L. Involvement of 5-HT1A and 5-HT2 receptors of the inferior colliculus in aversive states induced by exposure of rats to the elevated plus-maze test. Behav Pharmacol. 6:1995;413-417.
92. Menard J, Treit D. The septum and the hippocampus differentially mediate the anxiolytic effects of R(+)-8-OH-DPAT. Behav. Pharmacol., in press.
93. Mohler H., Okada T. Benzodiazepine receptor: demonstration in the central nervous system. Science. 198:1997;849-851.
94. Motta V., Brandao M. L. Aversive and antiaversive effects of morphine in the dorsal periaqueductal gray of rats submitted to the elevated plus-maze test. Pharmacol Biochem Behav. 44:1993;119-125.
95. Mueller E. A., Murphy D. L., Sunderland T. Neuroendocrine effects of m-chlorophenylpiperazine, a serotonin agonist, in humans. J Clin Endocrinol Metab. 61:1985;1179-1184.
96. Myers RD. Handbook of drug and chemical stimulation of the brain: behavioural, pharmacological and physiological aspects. New York: Van Nostrand Reinhold, 1974.
97. Nagy J., Zambo K., Decsi L. Anti-anxiety action of diazepam after intra-amygdaloid application in the rat. Neuropharmacology. 18:1979;573-576.
98. Niehoff D. L., Kuhar M. J. Benzodiazepine receptors: localization in rat amygdala. J Neurosci. 3:1983;2091-2097.
99. Palacios J. M., Waeber C., Hoyer D., Mengod G. Distribution of serotonin receptors. Ann NY Acad Sci. 600:1990;36-52.
100. Pazos A., Palacios J. M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res. 346:1985;205-230.
101. Pellow S. Anxiolytic and anxiogenic drug effects in a novel test of anxiety: are exploratory models of anxiety in rodents valid? Meth Find Exp Clin Pharmacol. 8:1986;557-565.
102. Pellow S., Chopin P., File S. E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Meth. 14:1985;149-167.
103. Pesold C., Treit D. The septum and amygdala differentially mediate the anxiolytic effects of benzodiazepines. Brain Res. 638:1994;295-301.
104. Pesold C., Treit D. The central and basolateral amygdala differentially mediate the anxiolytic effects of benzodiazepines. Brain Res. 671:1995;213-221.
105. Pesold C., Treit D. The neuroanatomical specificity of the anxiolytic effects of intra-septal infusions of midazolam. Brain Res. 710:1996;161-168.
106. Peterson E. N., Braestrup C., Scheel-Kruger J. Evidence that the anticonflict effect of midazolam in amygdala is mediated by the specific benzodiazepine receptors. Neurosci Lett. 53:1985;285-288.
107. Picazo O., Lopez-Rubalcava C., Fernandez-Gausti A. Anxiolytic effect of the 5-HT1A compounds 8-hydroxy-2-(di-n-propylamino)tetralin and ipsapirone in the social interaction paradigm: evidence of a presynaptic action. Brain Res Bull. 37:1995;169-175.
108. Plaznik A., Jessa M., Bidzinski A., Nazar M. The effect of serotonin depletion and intra-hippocampal midazolam on rat behaviour in the Vogel Conflict test. Eur J Pharmacol. 257:1994;293-296.
109. Pollard G. T., Howard J. L. Effects of drugs on punished behaviour: pre-clinical test for anxiolytics. Pharmacol Ther. 45:1990;403-424.
110. Przegalinski E., Tatarczynska E., Klodzinska A., Chojnacka-Wojcik E. The role of post-synaptic 5-HT1A receptors in the anticonflict effect of ipsapirone. Neuropharmacology. 33:1994;1109-1115.
111. Radja F., Laporte A., Daval G., Verge D., Gozlan H., Hamon M. Autoradiography of serotonin receptor subtypes in the central nervous system. Neurochem Int. 18:1991;1-15.
112. Rassnick S., Heinrichs S. C., Britton K. T., Koob G. F. Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res. 605:1993;25-32.
113. Remy S. M., Schreiber R., Dalmus M., De Vry J. Somatodendritic 5-HT1A receptors are critically involved in the anxiolytic effects of 8-OH-DPAT. Psychopharmacology. 125:1996;89-91.
114. Russo A. S., Guimaraes F. S., De Aguiar J. C., Graeff F. G. Role of benzodiazepine receptors located in the dorsal periaqueductal grey of rats in anxiety. Psychopharmacology. 110:1993;198-202.
115. Sananes C. B., Davis M. N-Methyl-D-aspartate lesions of the lateral and basolateral nuclei of the amygdala block fear-potentiated startle and shock sensitization of startle. Behav Neurosci. 106:1992;72-80.
116. A and benzodiazepine receptor antagonists in the region of the anterior basolateral amygdala of rats. Biol Psychiat. 37:1995;473-476.
117. Scheel-Kruger J., Petersen E. N. Anticonflict effect of the benzodiazepines mediated by a GABAergic mechanism in the amygdala. Eur J Pharmacol. 82:1982;115-116.
118. Schreiber R., De Vry J. Neuronal circuits involved in the anxiolytic effects of the 5-HT1A receptor agonists 8-OH-DPAT, ipsapirone and buspirone in the rat. Eur J Pharmacol. 249:1993;341-351.
119. Shephard R. A. Neurotransmitters, anxiety and benzodiazepines: a behavioural review. Neurosci Biobehav Rev. 10:1986;449-461.
120. Shibata S., Kataoka Y., Gomita Y., Ueki S. Localization of the site of the anticonflict action of benzodiazepines in the amygdaloid nucleus of rats. Brain Res. 234:1982;442-446.
121. Shibata S., Yamashita K., Yamamoto E., Oazki T., Ueki S. Effects of benzodiazepine and GABA antagonists on anticonflict effects of antianxiety drugs injected into the rat amygdala in a water-lick suppression test. Psychopharmacology. 98:1989;38-44.
122. Sinton C. M., Fallon S. L. Electrophysiological evidence for a functional differentiation between subtypes of the 5-HT 1 receptor. Eur J Pharmacol. 157:1988;173-181.
123. A receptors. Tips. 16:1995;162-168.
124. Sommermeyer H., Schreiber R., Greuel J., De Vry J., Glaser T. Anxiolytic effects of the 5-HT1A receptor agonist ipsapirone in the rat: neurobiological correlates. Eur J Pharmacol. 240:1993;29-37.
125. Soubrie P., Theibot M. H., Jobert A., Hamon M. Serotonergic control of punished behaviour: effects of intra-raphe microinjections of chlordiazepoxide, GABA and 5-HT on behavioural suppression in rats. J Physiologie. 77:1981;449-453.
126. Sprouse J S., Aghajanian G. K. Electrophysiological responses of serotonergic dorsal raphe neurons to 5-HT 1A and 5-HT 1B agonist. Synapse. 1:1987;3-9.
127. Squires R. F., Braestrup C. Benzodiazepine receptors in rat brain. Nature. 266:1977;732-734.
128. Stefanski R., Palejko W., Bidzinski A., Kostowski W., Plaznik A. Serotonergic innervation of the hippocampus and nucleus accumbens septi and the anxiolytic-like action of midazolam and 5-HT1A receptor agonists. Neuropharmacology. 32:1993;977-985.
129. Stefanski R., Palejko W., Bidzinski A., Kostowski W., Plaznik A. Serotonergic innervation of the hippocampus and nucleus accumbens septi and the anxiolytic-like action of the 5-HT3 receptor antagonists. Neuropharmacology. 32:1993;987-993.
130. Swiergiel A. H., Takahashi L. K., Kalin N. H. Attenuation of stress-induced behaviour by antagonism of corticotropin-releasing factor receptors in the central amygdala in the rat. Brain Res. 623:1993;229-234.
131. Swiergiel A. H., Takahashi L. K., Rubin W. W., Kalin N. H. Antagonism of corticotropin-releasing factor receptors in the locus ceruleus attenuates shock-induced freezing in rats. Brain Res. 587:1992;263-268.
132. Thiebot M. H., Hamon M., Soubrie P. Attenuation of induced-anxiety in rats by chlordiazepoxide: role of raphe dorsalis benzodiazepine binding sites and serotonergic neurons. Neuroscience. 7:1982;2287-2294.
133. Thiebot M. H., Jobert A., Soubrie P. Chlordiazepoxide and GABA injected into raphe dorsalis release the conditioned behavioural suppression induced in rats by a conflict procedure without nociceptive component. Neuropharmacology. 19:1980;633-641.
134. Thiebot M. H., Jobert A., Soubrie P. Conditioned suppression of behaviour: its reversal by intra raphe microinjection of chlordiazepoxide and GABA. Neurosci Lett. 16:1980;213-217.
135. Thiebot M. H., Soubrie P., Hamon M., Simon P. Evidence against the involvement of serotonergic neurons in the anti-punishment activity of diazepam in the rat. Psychopharmacology. 82:1984;355-359.
136. Thiebot M. H., Soubrie P., Sanger D. Anxiogenic properties of beta-CCE and FG 7142: a review of promises and pitfalls. Psychopharmacology. 94:1988;452-463.
137. 3H]Diazepam binding density with anxiolytic locus in the amygdaloid complex of the rat. Brain Res. 342:1985;85-90.
138. Tomkins D. M., Costall B., Kelly M. E. Release of suppressed behaviour of rat on the elevated X-maze by 5-HT3 receptor antagonists injected into the basolateral amygdala. J Psychopharmacol. 4:1990;262P.
139. Treit D. A comparison of anxiolytic and nonanxiolytic agents in the shock-probe/burying test for anxiolytics. Pharmacol Biochem Behav. 36:1990;203-205.
140. Treit D. Animal models of anxiety and anxiolytic drug action. In: den Boer JA, Ad Sitsen JM, editors. Handbook of depression and anxiety: a biological approach. New York: Marcel Dekker, 1994:201-224.
141. Treit D. Animal models for the study of anti-anxiety agents: a review. Neurosci Biobehav Rev. 9:1985;203-222.
142. 1A agonists, 5-HT3 antagonists and benzodiazepines: their comparative behavioural pharmacology. New York: Wiley, 1991:107-131.
143. Treit D., Fundytus M. A comparison of buspirone and chlordiazepoxide in the shock-probe/burying test anxiolytics. Pharmacol Biochem Behav. 30:1988;1071-1075.
144. Treit D., Fundytus M. Thigmotaxis as a test for anxiolytic activity in rats. Pharmacol Biochem Behav. 31:1988;959-962.
145. Treit D, Menard J., Animal models of anxiety and depression. In: Boulton A, Baker GB, Bateson AN, editors. Neuromethods, vol. 32: In vivo neuromethods. New Jersey: Humana Press, 1998:89-148.
146. Treit D., Menard J. The anxiolytic effects of R(+)-8-OH-DPAT differ in the septum and in the amygdala. Neuroscience Abstract. 22:1996;1136.
147. Treit D., Menard J., Pesold C. The shock-probe burying test. Neurosci Protocols Module. 3:1994;9-17.
148. 1A receptor ligands on rat dorso-lateral septal neurones in vitro. Br J Pharmacol. 106:1992;893-899.
149. Vogel J. R., Beer D., Clody D. E. A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacology. 71:1971;123-129.
150. Wahlestedt C., Pich E. M., Koob G. F., Lee F., Heilig M. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science. 259:1993;528-531.
151. Whitton P., Curzon G. Anxiogenic-like effect of infusing 1-(3-chlorophenyl)piperazine (mCPP) into the hippocampus. Psychopharmacology. 100:1990;138-140.
152. Wright D. E., Seroogy K. B., Lundgren K. H., Davis B. M., Jennes L. Comparative localization of serotonin 1A, 1C, and 2 receptor subtype mRNAs in rat brain. J Comp Neurol. 351:1995;357-373.
153. Young S., Kuhar M. J. Radiohistochemical localization of benzodiazepine receptors in rat brain. J Pharmacol Exp Ther. 212:1980;337-346.
154. Zangrossi H. Jr., Graeff F. G. Behavioural effects of intra-amygdala injections of GABA and 5-HT acting drugs in the elevated plus-maze. Braz J Med Biol Res. 27:1994;2453-2456.
155. Zifa E., Fillion G. 5-Hydroxytryptamine receptors. Pharmacol Rev. 44:1992;401-458.
156. Zorumski C. F., Isenberg K. E. Insights into the structure and function of GABA-Benzodiazepine receptors: ion channels and psychiatry. Am J Psychiatry. 148:1991;162-173.